-
Yamal off the mark at World Cup as Spain thrash Saudi Arabia
-
Yamal off mark at World Cup as Spain thrash Saudi
-
Yamal scores on injury return as Spain thrash Saudi Arabia
-
Noskova overpowers Pegula to win Berlin WTA
-
Iran warns US to 'be careful' after Trump threat
-
Gakpo savours 'freedom' to fire Dutch in World Cup title bid
-
Cerundolo outlasts Paul to win marathon Queen's Club final
-
Pogacar wins final stage to seal Tour of Switzerland success
-
Henry the hero for New Zealand as England bring back Stokes
-
Bolivia removes roadblocks after emergency decree
-
Vance hopes US, Iran can turn 'new leaf' with talks
-
Europe sweats through new heatwave, with worse to come
-
Trump-backed hardliner faces leftist senator as Colombia votes
-
Japan striker Ueda channels frustration to send World Cup warning
-
Dominant Tiafoe swats aside Fritz to win Halle Open
-
France hosts street music festival despite worsening heatwave
-
India hails Sooryavanshi after record 11-ball half-century
-
Swiss US-Iran talks venue a playground of world leaders, movie stars
-
Yamal returns to kickstart Spain attack against Saudi Arabia
-
Colombians vote in presidential runoff
-
Nigerian twins Taiwo and Kehinde marry... Taiwo and Kehinde
-
Marc Marquez wins Czech MotoGP to close gap on banned Bezzecchi
-
France presses ahead with street music festival despite extreme heat
-
Marc Marquez wins Czech MotoGP as Bezzecchi banned
-
'Historical justice': Dutch PM makes formal apology to Moluccans
-
Stokes to return as England captain for 3rd New Zealand Test - McCullum
-
Henry the hero as New Zealand level England series in style
-
Britain's King Charles to reveal personal tax bill: Palace
-
Gill to skipper India against England, Kohli to play if fit
-
France presses ahead with street music festivals despite extreme heat
-
UK's Starmer mulling 'political realities': senior minister
-
England's Stokes and Atkinson withdrawn from county games ahead of 3rd Test
-
France presses ahead with music festivals despite extreme heat
-
Ukrainian strikes on Russian-annexed Crimea kill 4, pause fuel sales
-
Springboks recall 'outstanding' Papier for Nations Championship
-
US, Iran set for talks as Lebanon conflict threatens deal
-
Bezzecchi out of Czech MotoGP after slapping steward
-
Spain target convincing win to dispel World Cup doubts
-
FIFA draws criticism as Infantino clocks up air miles at World Cup
-
Curacao keeper Room jokes he deserves statue after World Cup heroics
-
Japan stroll to victory over Tunisia in World Cup's 1,000th game
-
Pakistan's mango exports shrink as Middle East war impacts linger
-
Trump blames 'terrible vandals' for Washington pool renovation woes
-
Iran World Cup travel restrictions to be eased, says coach
-
Man charged over suspected anti-Muslim attacks in Edinburgh
-
Room heroics earn Curacao World Cup point against Ecuador
-
Britain's King Charles to reveal personal tax bill: reports
-
New mindset, prior win give Clark confidence at US Open
-
Fly-half Love ready for All Blacks start after Super Rugby heroics
-
Scheffler eager to seize the moment as career slam beckons
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
F.Pavlenko--BTB